secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001193125-24-197821
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory
-------------------------------------------------------------------------------

- Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.
- Paul Thomas appointed Chair of the Board, effective August 9, 2024; he joined the Board in 2020.
- Dale receives $765k base salary, 100% target bonus, and 600,000 PSUs tied to stock price goals and Avance Nerve Graft BLA approval.
- Dale has 30+ years med device experience, most recently President of structural heart at Abbott (NYSE: ABT).
- Zaderej remains in advisory role for nine months under a previously disclosed Transition and Separation Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000119312524197821/0001193125-24-197821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000119312524197821/d831362d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer